Senti Biosciences, Inc. (SNTI)Healthcare | Biotechnology | South San Francisco, United States | NasdaqCM
1.10 USD
+0.14
(14.381%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 1.09 -0.01 (-0.010%) ⇩ (April 17, 2026, 7:49 p.m. EDT) Short-term: ★☆☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 10:13 p.m. EDT
Avoid SNTI; despite FDA approval news and a reorg, the stock trades at a massive premium (1557x P/S) with negative earnings, prohibitive debt, massive cash burn, and a forecasting model explicitly predicting a downside scenario in the near term. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.147503 |
| AutoARIMA | 0.148087 |
| MSTL | 0.169704 |
| AutoTheta | 0.238207 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 62% |
| H-stat | 1.86 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.737 |
| Excess Kurtosis | -0.20 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 516.926 |
| Revenue per Share | 0.001 |
| Market Cap | 34,258,948 |
| Forward P/E | -1.23 |
| Beta | 2.12 |
| Website | https://www.sentibio.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.7229219 |
| Address1 | 2 Corporate Drive |
| Address2 | First Floor |
| All Time High | 105.4 |
| All Time Low | 0.77 |
| Ask | 1.15 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 175,290 |
| Average Daily Volume3 Month | 175,641 |
| Average Volume | 175,641 |
| Average Volume10Days | 175,290 |
| Beta | 2.119 |
| Bid | 1.07 |
| Bid Size | 1 |
| Book Value | 0.181 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.1 |
| Current Ratio | 1.666 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 1.13 |
| Day Low | 1.0001 |
| Debt To Equity | 516.926 |
| Display Name | Senti Biosciences |
| Earnings Timestamp End | 1,755,547,260 |
| Earnings Timestamp Start | 1,755,115,260 |
| Ebitda | -54,667,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.849 |
| Enterprise To Revenue | 2,109.77 |
| Enterprise Value | 46,414,948 |
| Eps Current Year | -1.09333 |
| Eps Forward | -0.895 |
| Eps Trailing Twelve Months | -2.73 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.90842 |
| Fifty Day Average Change | 0.19158 |
| Fifty Day Average Change Percent | 0.21089363 |
| Fifty Two Week Change Percent | -72.29219 |
| Fifty Two Week High | 5.1 |
| Fifty Two Week High Change | -4.0 |
| Fifty Two Week High Change Percent | -0.78431374 |
| Fifty Two Week Low | 0.77 |
| Fifty Two Week Low Change | 0.33000004 |
| Fifty Two Week Low Change Percent | 0.4285715 |
| Fifty Two Week Range | 0.77 - 5.1 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,622,035,800,000 |
| Float Shares | 14,577,493 |
| Forward Eps | -0.895 |
| Forward P E | -1.2290503 |
| Free Cashflow | -23,338,000 |
| Full Exchange Name | NasdaqCM |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -37,564,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.47596002 |
| Held Percent Institutions | 0.18451999 |
| Implied Shares Outstanding | 31,144,497 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,721,260,800 |
| Last Split Factor | 1:10 |
| Long Business Summary | Senti Biosciences, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. Its lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. The company's product candidates also include SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers and relapsed/refractory hematological malignancies, including acute myeloid leukemia; and SENTI-301A, an off-the-shelf CAR-NK cell therapy for the treatment of solid tumors and hepatocellular carcinoma. In addition, it develops the tumor-associated antigen and protective antigen paired discovery platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Further, its pipeline includes preclinical programs, which comprise a solid tumor cell therapy program; and partnered programs related to gene therapies for tissue-directed targets, as well as partnered programs related to cell therapies for regenerative medicines. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. |
| Long Name | Senti Biosciences, Inc. |
| Market | us_market |
| Market Cap | 34,258,948 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_538838857 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -61,438,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 34,258,946 |
| Number Of Analyst Opinions | 4 |
| Open | 1.02 |
| Operating Cashflow | -43,444,000 |
| Operating Margins | -370.95453 |
| Payout Ratio | 0.0 |
| Phone | 650 239 2030 |
| Post Market Change | -0.00999999 |
| Post Market Change Percent | -0.90909004 |
| Post Market Price | 1.09 |
| Post Market Time | 1,776,469,785 |
| Previous Close | 0.9617 |
| Price Eps Current Year | -1.0061007 |
| Price Hint | 4 |
| Price To Book | 6.077348 |
| Price To Sales Trailing12 Months | 1,557.2249 |
| Profit Margins | 0.0 |
| Quick Ratio | 1.312 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.1383 |
| Regular Market Change Percent | 14.3808 |
| Regular Market Day High | 1.13 |
| Regular Market Day Low | 1.0001 |
| Regular Market Day Range | 1.0001 - 1.13 |
| Regular Market Open | 1.02 |
| Regular Market Previous Close | 0.9617 |
| Regular Market Price | 1.1 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 918,672 |
| Return On Assets | -0.48891997 |
| Return On Equity | -2.18082 |
| Revenue Per Share | 0.001 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 31,144,497 |
| Shares Percent Shares Out | 0.023599999 |
| Shares Short | 736,084 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 813,632 |
| Short Name | Senti Biosciences, Inc. |
| Short Percent Of Float | 0.0238 |
| Short Ratio | 6.82 |
| Source Interval | 15 |
| State | CA |
| Symbol | SNTI |
| Target High Price | 15.0 |
| Target Low Price | 6.0 |
| Target Mean Price | 11.0 |
| Target Median Price | 11.5 |
| Total Cash | 16,735,000 |
| Total Cash Per Share | 0.537 |
| Total Debt | 28,891,000 |
| Total Revenue | 22,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.73 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.438955 |
| Two Hundred Day Average Change | -0.33895493 |
| Two Hundred Day Average Change Percent | -0.23555632 |
| Type Disp | Equity |
| Volume | 918,672 |
| Website | https://www.sentibio.com |
| Zip | 94,080 |